Previous 10 | Next 10 |
Thesis that FDA approval of Fintepla would immediately unlock value was wrong. With ZGNX down nearly 40% since, and the story still fully intact, the stock is now highly attractive. The recent $200M convertible debt deal surprised many. This large capital raise, on top of the $399...
YouTuber Boston Biotech Investor posted this review of Zogenix on his YouTube channel today. The stock has been hit due to dilution as a result of the $200M convertible debt offering it price yesterday, as we reported. Here's Boston Biotech Investor's analysis: For further details see: ...
Zogenix (ZGNX) prices $200M 2.75% convertible senior notes due 2027 in a private offering to institutional buyers.Initial purchasers has an option an additional $30M From and after July 1, 2027, noteholders may convert their notes at any time at their election until the close of bu...
EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional ...
Gainers: [[NKE]] +10.9%. [[BZH]] +7.3%. [[AROC]] +7.3%. [[EQX]] +6.4%. [[RPAI]] +5.0%.Losers: [[WVE]] -24.2%. [[SFIX]] -16.7%. [[ACB]] -15.4%. [[ZGNX]] -8.3%. [[SCS]] -7.2%. For further details see: NKE, EQX, SFIX and ZGNX among after-hours movers
Zogenix ([[ZGNX]] -1.1%) plans to offer $200M principal amount of convertible senior notes due 2027 in a private offering to institutional buyers.Interest rate, initial conversion rate to be determined at pricing. Initial purchasers' additional option is $30M of notes.The company intends...
EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offe...
Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows. EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global bio...
EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its...
Ligand inks deal to acquire Taurus and xCella Biosciences Ligand Pharmaceuticals Inc. ( LGND ) reported that it has inked a deal to acquire two companies, xCella Biosciences Inc. and Taurus Biosciences. Both these companies are privately held and are expected to boost Ligand’s Omn...
News, Short Squeeze, Breakout and More Instantly...
UCB Completes Acquisition of Zogenix, Inc. - Broadens and builds upon UCB's role as a leader in, and our continued commitment to, addressing unmet needs of people living with epilepsy - Total transaction value of up to approximately US$ 1.9 billion / € 1.7 billion. Th...
Zogenix Inc. (NASDAQ:ZGNX) traded today at a new 52-week high of $26.66. Approximately 1.2 million shares have changed hands today, as compared to an average 30-day volume of 3.7 million shares. Zogenix Inc. (NASDAQ:ZGNX) defies analysts with a current price ($26.57) 0.4% above its avera...
Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS patients LGS is a debilitating childhood-onset developmental and epileptic encephalopathy estimated to affect approx...